

ORAL PRESENTATION

Open Access

O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists

CJ Brumme^{1*}, W Dong¹, D Chan¹, T Mo¹, LC Swenson¹, C Woods¹, J Demarest², J Heera³, H Valdez⁴, PR Harrigan¹

From Tenth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 7-11 November 2010

Background

Spontaneous tropism changes (from R5 to non-R5 or vice-versa) were observed in approximately 10% of patients between screening and study baseline in the maraviroc (MVC) clinical trials. Little is known of the biology of these apparent short-term tropism fluctuations.

Methods

Population-based and “deep” V3-loop sequencing were performed in 53 MVC recipients in the MERIT, MOTIVATE and A4001029 studies who spontaneously changed tropism readout by the original Trofile assay between screening and baseline (~4-8 weeks) and 72 randomly sampled patients who did not change. Tropism was inferred by “geno2pheno” with previously defined cutoffs: 2% X4 prevalence with a 3.5% false-positive rate (fpr) for “deep” sequencing; 5.75% fpr for population-based sequencing.

Results

Patients changing Trofile readout from R5 to non-R5 had significantly higher screening non-R5 prevalence by “deep” sequencing than those who remained R5, and this increased slightly by the baseline timepoint (Table 1).

Similarly, patients who changed tropism from non-R5 to R5 in the A4001029 trial had a lower percentage of non-R5 viruses at screening and baseline. Although there was no difference in total viral load, absolute CXCR4-using plasma virus load was higher in those who changed tropism at screening (2.7 vs. 0 log₁₀ copies/mL, p=0.02 in MERIT; 3.1 vs. 0 log₁₀ copies/mL, p<0.0001 in MOTIVATE) and baseline (3.0 vs. 0 log₁₀ copies/mL, p=0.04 in MERIT; 3.8 vs. 0 log₁₀ copies/mL, p<0.0001 in MOTIVATE). Non-R5 was reported at screening in 26% and 49% of patients who changed phenotype to non-R5 by population and deep-sequencing, respectively.

Conclusions

In most cases, the prevalence of non-CCR5 usage inferred from “deep” sequencing was stable over the short term between screening and baseline. Where apparent phenotypic tropism changes from R5 to non-R5 occurred, non-R5 virus was generally detectable at the screening timepoint by genotype, coupled with relatively small increases in non-R5 virus by baseline. Small variations in CXCR4-using HIV populations around the phenotypic assay detection limit, rather than coreceptor switch, contributed to apparent tropism switching from R5 to non-R5.

Table 1

	# Genotyped		Screening X4% [IQR]			Baseline X4% [IQR]		
	No Change	Changed	No Change	Changed	p	No Change	Changed	p
MERIT	25	13	0 [0-0]	1.9 [0-3.3]	0.01	0 [0-0.1]	7 [0-16.3]	0.04
MOTIVATE	25	32	0 [0-0.1]	2.4 [0.1-21.3]	0.0001	0 [0-0.1]	9.1 [0.4-32.7]	<0.0001
A4001029	22	8	5.0 [0.2-91.5]	1.8 [0.4-30.6]	0.5	4.3 [0-76.6]	0.4 [0-47.5]	0.3

¹BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
Full list of author information is available at the end of the article

Author details

¹BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. ²ViiV Healthcare, Research Triangle Park, USA. ³Pfizer Global R&D, New London, USA. ⁴Pfizer Inc., New York, USA.

Published: 8 November 2010

doi:10.1186/1758-2652-13-S4-O9

Cite this article as: Brumme *et al.*: O123. Short-term variation of HIV tropism readouts in the absence of CCR5 antagonists. *Journal of the International AIDS Society* 2010 **13**(Suppl 4):O9.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

